Have a feature idea you'd love to see implemented?
Let us know!
IKNA Ikena Oncology Inc
Price (delayed)
$1.73
Market cap
$83.49M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.22
Enterprise value
$46.69M
Ikena Oncology is a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena is advancing five programs that
Highlights
The debt has contracted by 27% YoY and by 8% from the previous quarter
IKNA's EPS is up by 25% year-on-year and by 13% since the previous quarter
IKNA's quick ratio is up by 46% year-on-year but it is down by 16% since the previous quarter
IKNA's gross profit has shrunk by 95% YoY and by 64% QoQ
Ikena Oncology's revenue has shrunk by 95% YoY and by 64% QoQ
Key stats
What are the main financial stats of IKNA
Market
Valuations
Earnings
Shares outstanding
48.26M
Market cap
$83.49M
Enterprise value
$46.69M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.62
Price to sales (P/S)
126.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
70.85
Revenue
$659,000
EBIT
-$59.66M
EBITDA
-$56.87M
Free cash flow
-$61.39M
Per share
Balance sheet
Liquidity
EPS
-$1.22
Free cash flow per share
-$1.27
Book value per share
$2.78
Revenue per share
$0.01
TBVPS
$3.09
Total assets
$148.99M
Total liabilities
$14.76M
Debt
$8.39M
Equity
$134.23M
Working capital
$132.29M
Debt to equity
0.06
Current ratio
15.32
Quick ratio
14.94
Net debt/EBITDA
0.65
Margins
Efficiency
Dividend
EBITDA margin
-8,629.4%
Gross margin
100%
Net margin
-9,043.9%
Operating margin
-10,373.9%
Return on assets
-35.5%
Return on equity
-39.6%
Return on invested capital
-58.9%
Return on capital employed
-42.7%
Return on sales
-9,053.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IKNA stock price
How has the Ikena Oncology stock price performed over time
Intraday
1.76%
1 week
1.17%
1 month
2.37%
1 year
8.13%
YTD
-12.18%
QTD
0%
Financial performance
How have Ikena Oncology's revenue and profit performed over time
Revenue
$659,000
Gross profit
$659,000
Operating income
-$68.36M
Net income
-$59.6M
Gross margin
100%
Net margin
-9,043.9%
Ikena Oncology's operating margin has plunged by 154% from the previous quarter
The net margin has plunged by 150% from the previous quarter
IKNA's gross profit has shrunk by 95% YoY and by 64% QoQ
Ikena Oncology's revenue has shrunk by 95% YoY and by 64% QoQ
Growth
What is Ikena Oncology's growth rate over time
Valuation
What is Ikena Oncology stock price valuation
P/E
N/A
P/B
0.62
P/S
126.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
70.85
IKNA's EPS is up by 25% year-on-year and by 13% since the previous quarter
The stock's price to book (P/B) is 24% more than its last 4 quarters average of 0.5
IKNA's equity is down by 14% year-on-year and by 6% since the previous quarter
The P/S is 158% higher than the last 4 quarters average of 49.2
Ikena Oncology's revenue has shrunk by 95% YoY and by 64% QoQ
Efficiency
How efficient is Ikena Oncology business performance
IKNA's return on sales has dropped by 150% since the previous quarter
Ikena Oncology's ROIC has increased by 14% from the previous quarter and by 8% YoY
Ikena Oncology's ROE has increased by 7% from the previous quarter and by 6% YoY
Dividends
What is IKNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IKNA.
Financial health
How did Ikena Oncology financials performed over time
Ikena Oncology's total liabilities has decreased by 48% YoY
IKNA's current ratio is up by 47% YoY but it is down by 16% QoQ
The debt is 94% less than the equity
The debt has contracted by 27% YoY and by 8% from the previous quarter
Ikena Oncology's debt to equity has decreased by 14% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.